Summary: A CDMO’s role in the pharmaceutical supply chain extends well beyond development and manufacturing. It also involves coordinating the people, materials, data, and decisions required to keep complex programs moving efficiently. In this blog, Robert Cornog, Senior Director of Product Development, and Omer Alp, Director of Integrated Planning and Continuous Improvement, discuss how CDMOs help manage complexity across the pharmaceutical value chain, from raw materials through commercially ready drug products, while applying actionable data and disciplined project management across supporting functions.
At each stage of development, manufacturing, and testing for drug products, CDMOs are an integral part of the wider array of pharma supply chain partners
While progressing through later stage clinical testing and approaching commercialization, sponsors face pressure to integrate key activities across quality, operations, supply chain, analytical testing, and logistics. Each touchpoint increases the complexity and requirements around exchanging information, while adding time and risk for decision making in the pharmaceutical value chain.
Quotient Sciences supports this model with an ever-evolving framework for commercial readiness. Leveraging visual dashboards and business intelligence to connect data from quality, supply chain and operations, QC, and project management functions allows us to:
- Manage raw material, excipients, and packaging components inventory risk, material readiness, material-related delays, and incoming release adherence to support production planning
- Adjust to changes in drug substance manufacturing campaigns, availability, shifts in material attributes and delivery timelines
- Align critical document review for drug product manufacturing, analytical testing, stability data review, and third-party laboratory activities
- Use program-specific forecasting and batch tracking to provide sponsors with visibility to quality trends, execution status, and capacity planning
- Manage logistics for delivery to clinical sites, packaging partners, labeling providers, depots, or downstream distribution partners
Without integrated visibility, sponsors may increase the risk of miscommunication and miss opportunities for real-time decision making, leading to delayed batch delivery, critically low clinical stocks, delayed program milestones (e.g., delay to commercial launch), and audit readiness challenges.
A shift to a proactive approach
Through our integrated program approach, we frequently use program-specific dashboards and data visualizations to give clients greater visibility during project progression. This helps identify where delays may occur and resources must be prioritized, and whether improvements are sustained over time.
Recently, we have embedded key performance indicators (KPIs) into each commercial program we support at Quotient Sciences – Philadelphia.
KPIs covering the scope of services are monitored, tracked, and trended. Using a centralized analytical platform, we share these metrics and bespoke dashboards with sponsors, relevant project team members, and site leadership to ensure activities progress and programs stay on schedule.
Industry standard indicators often include:
- Vendor/third party performance
- Production schedule adherence
- Manufacturing and laboratory capacities
- Analytical turnaround times
- Documentation review cycle time
- Quality event trending
- Operational department workloads
- Batch release cycle time
- On-Time-In-Full (OTIF) delivery
- Right First Time (RFT)
Real-time data allows technical teams and stakeholders from both sides to review data, detect potential issues, and adapt their programs. Additionally, we have customized KPI reporting for customers based on master service agreements or other governing contacts.
Increased visibility and use of operational metrics have allowed our Philadelphia team to identify schedule risks earlier, evaluate sources of inefficiency, conduct root cause analysis, and prioritize further process improvements for our commercial drug product programs, especially. Integrated planning dashboards have helped convert operational data into earlier decision points in many programs this year at our Boothwyn and Garnet Valley, PA CDMO manufacturing sites in the greater Philadelphia area. For example:
-Schedule visibility and adherence: Structured governance and routine KPI review supported faster cross-functional decision-making and improved visibility to scheduled activities. It also increased manufacturing schedule adherence by about 50% across the entire site over 4 months and sustained performance in 12 months.
-Vendor and material release performance: Vendor performance benchmarking enabled redirection of outsourced activities across the commercial portfolio to alternate vendors within the qualified supplier network, helping avoid bottlenecks. In the first half of 2026, site-wide, we improved on time release rate of incoming raw material lots by 25%.
-Quality event reduction: Dashboard visuals and quality data trending helped with quality improvement efforts across multiple operational groups at our US drug product manufacturing sites. With increased management visibility, quality groups collaborated with technical teams to provide an actionable plan to control and reverse adverse trends. These efforts supported a 66% reduction in monthly open events, increasing quality compliance and regulatory adherence.
-Documentation Accuracy and Review Efficiency: Trending of documentation review data enabled teams to identify targeted improvements and increase workflow efficiency. Applying these insights to document corrections and templated updates reduced on-the-floor documentation errors, streamlined reviews, and strengthened quality and regulatory compliance. Specifically, when applied to executable commercial production records, errors identified during technical review were decreased by 80% between two different product lines.
Real Time Transparency
The risk of delays is ever-present, making ongoing management and effective communication between teams critical.
Project managers at Quotient Sciences bring together various functions, ensuring roles are clear and keeping teams working toward a common plan, with transparency at every stage. Every customer has a designated project team for continuity, accountability, direct communication with technical experts, and program oversight to effectively manage time, cost, and quality.
Quotient Sciences project managers are also skilled at vendor management for any third-party services required. This takes the complexity and burden of managing multiple vendors off the customer, for a streamlined approach to product delivery.
For example, when batch release timing for a routine commercial product began affecting downstream packaging and labeling activities, Quotient Sciences used supply chain performance monitoring to identify that increased turnaround times at a client-managed analytical testing laboratory were the primary constraint.
Adjusting the drug product manufacturing schedule to better align batch release sample testing with packaging timelines, we enabled more consistent deliveries and reduced the client’s overhead by eliminating packaging delay charges.
Ensuring resiliency across the pharma supply chain
Pharmaceutical supply chain resiliency depends on the ability to see risks early, coordinate activities across functions, and consistently execute – even when program complexity increases. Disruptions can occur at any point, from raw material or API supply, through quality review, production scheduling, packaging, or regulatory release.
While manufacturing remains a core CDMO capability, the ability to coordinate people, materials, data, decisions, and external partners adds critical value for sponsors. By combining project management discipline with business intelligence, CDMOs can help transform supply chain complexity into actionable control.
As a drug product CDMO, Quotient Sciences supports this by actively managing stakeholders, implementing robust CMC strategies, and providing comprehensive operational oversight across multiple partners and interfaces. Learn more about our drug product manufacturing capabilities and global locations.